Fenugreek: A therapeutic complement for patients with borderline hyperlipidemia: A randomised, double-blind, placebo-controlled, clinical trial

Fenugreek (Trigonella foenum-graecum) is a medicinal plant from Fabaceae family. This clinical study was designed to evaluate the effects of Fenugreek seeds supplementation on serum biochemical parameters of patients with borderline hyperlipidemia. A randomised, double-blind, placebo-controlled clinical trial was conducted on 56 patients with borderline hyperlipidemia that were divided in two groups: F group received 8 g Fenugreek seeds powder sachets and P group received placebo sachets daily for 8 weeks. After 2 months, triglycerides (TG), total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), fasting blood glucose (FBG) and body mass index (BMI) were evaluated and compared with the baseline. After 2 months, TG, TC, LDL and FBG significantly decreased in F group in comparison with P group, but these changes were not significant in HDL and BMI. Our findings showed that Fenugreek seeds supplementation, as a phenolic-rich herb can be effective in the reduction of some lipid profile in patients with borderline hyperlipidemia.